NO2022002I1 - tasipimidine optionally in the form of a pharmaceutically acceptable salt thereof, in particular tasipimidine sulfate - Google Patents

tasipimidine optionally in the form of a pharmaceutically acceptable salt thereof, in particular tasipimidine sulfate

Info

Publication number
NO2022002I1
NO2022002I1 NO2022002C NO2022002C NO2022002I1 NO 2022002 I1 NO2022002 I1 NO 2022002I1 NO 2022002 C NO2022002 C NO 2022002C NO 2022002 C NO2022002 C NO 2022002C NO 2022002 I1 NO2022002 I1 NO 2022002I1
Authority
NO
Norway
Prior art keywords
tasipimidine
sulfate
optionally
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NO2022002C
Other languages
English (en)
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of NO2022002I1 publication Critical patent/NO2022002I1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
NO2022002C 2012-04-02 2022-01-27 tasipimidine optionally in the form of a pharmaceutically acceptable salt thereof, in particular tasipimidine sulfate NO2022002I1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261619109P 2012-04-02 2012-04-02
PCT/FI2013/000013 WO2013150173A1 (en) 2012-04-02 2013-03-28 New alpha2 adrenoceptor agonists

Publications (1)

Publication Number Publication Date
NO2022002I1 true NO2022002I1 (no) 2022-01-27

Family

ID=48224812

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2022002C NO2022002I1 (no) 2012-04-02 2022-01-27 tasipimidine optionally in the form of a pharmaceutically acceptable salt thereof, in particular tasipimidine sulfate

Country Status (26)

Country Link
US (1) US9249127B2 (no)
EP (1) EP2834233B1 (no)
JP (1) JP6427096B2 (no)
KR (1) KR102104228B1 (no)
CN (1) CN104220437B (no)
AR (1) AR090557A1 (no)
AU (1) AU2013244859B2 (no)
BR (1) BR112014023957B1 (no)
CA (1) CA2868611C (no)
DK (1) DK2834233T3 (no)
ES (1) ES2674945T3 (no)
FR (1) FR22C1005I1 (no)
HK (1) HK1205115A1 (no)
HR (1) HRP20181203T1 (no)
HU (2) HUE039290T2 (no)
IL (1) IL234663B (no)
LT (2) LT2834233T (no)
MX (1) MX358429B (no)
NL (1) NL301160I2 (no)
NO (1) NO2022002I1 (no)
PL (1) PL2834233T3 (no)
PT (1) PT2834233T (no)
RU (1) RU2642065C2 (no)
SI (1) SI2834233T1 (no)
TW (1) TWI620746B (no)
WO (1) WO2013150173A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015152196A1 (ja) * 2014-03-31 2015-10-08 東レ株式会社 イミダゾリン誘導体及びその医薬用途
EA201791804A1 (ru) * 2015-02-11 2018-02-28 Суновион Фармасьютикалз Инк. Соединения 1-гетероциклил изохроманила и аналоги для лечения расстройств цнс
CN105646306B (zh) * 2015-12-11 2020-06-30 广东莱佛士制药技术有限公司 一种4-甲硫基苯乙酸的制备方法
PT3717476T (pt) * 2017-12-01 2022-08-23 Orion Corp Processo para a preparação de 2-(5-metoxiisocroman-1-il)-4,5-di-hidro-1h-imidazol e o sal de hidrogenossulfato do mesmo
CN110272407B (zh) * 2019-07-22 2021-02-05 河北省农林科学院经济作物研究所 一种用于降血压的天然异色满酮类化合物
CA3212160A1 (en) 2021-03-19 2022-09-22 Johanna KUJALA Tasipimidine formulations and use thereof
WO2023139313A1 (en) 2022-01-24 2023-07-27 Orion Corporation Novel sulfate salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist
WO2023148431A1 (en) 2022-02-04 2023-08-10 Orion Corporation Novel salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist
WO2024069050A1 (en) 2022-09-28 2024-04-04 Orion Corporation Tasipimidine and cyp2d6 inhibitor combination treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1247008B (de) * 1965-10-05 1967-08-10 Huels Chemische Werke Ag Thermoplastische Massen zur Herstellung von vergilbungsfreien antielektrostatischen Formkoerpern aus Polyolefinen
US3438995A (en) * 1968-01-08 1969-04-15 Melville Sahyun Diazaheterocyclic substituted benz-oxaheterocyclic compounds
EP0166937B1 (en) * 1984-06-06 1991-08-28 Abbott Laboratories Adrenergic compounds
ES2216339T3 (es) * 1997-12-04 2004-10-16 Allergan, Inc. Derivados sustituidos de imidazol que tienen actividad de tipo agonista hacia los receptores adrenergicos alfa 2b o 2b/2c.
FI20000073A0 (fi) * 2000-01-14 2000-01-14 Orion Yhtymae Oy Uusia imidatsolijohdannaisia
CA2637261A1 (en) * 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of 2-imidazoles for the treatment of cns disorders
ES2338716T3 (es) 2006-01-27 2010-05-11 F.Hoffmann-La Roche Ag Uso de derivados de 4-imidazol para trastornos del snc.
CA2657481A1 (en) * 2006-07-21 2008-01-24 Queen's University At Kingston Methods and therapies for potentiating a therapeutic action of an alpha- 2 adrenergic receptor agonist and inhibiting and/or reversing tolerance to alpha- 2 adrenergic receptor agonists

Also Published As

Publication number Publication date
BR112014023957B1 (pt) 2022-03-29
JP6427096B2 (ja) 2018-11-21
HUE039290T2 (hu) 2018-12-28
US9249127B2 (en) 2016-02-02
HRP20181203T1 (hr) 2018-10-05
BR112014023957A8 (pt) 2021-06-15
HUS2200005I1 (hu) 2016-04-28
KR102104228B1 (ko) 2020-04-27
RU2642065C2 (ru) 2018-01-24
MX358429B (es) 2018-08-20
KR20140138826A (ko) 2014-12-04
AU2013244859B2 (en) 2017-06-22
SI2834233T1 (en) 2018-08-31
EP2834233B1 (en) 2018-04-25
FR22C1005I1 (fr) 2022-03-11
TWI620746B (zh) 2018-04-11
CA2868611A1 (en) 2013-10-10
NL301160I2 (nl) 2022-04-06
BR112014023957A2 (pt) 2017-06-20
CN104220437A (zh) 2014-12-17
PT2834233T (pt) 2018-07-17
AR090557A1 (es) 2014-11-19
DK2834233T3 (en) 2018-06-18
LTPA2022001I1 (no) 2022-02-25
HK1205115A1 (en) 2015-12-11
US20150065550A1 (en) 2015-03-05
EP2834233A1 (en) 2015-02-11
AU2013244859A1 (en) 2014-10-02
LT2834233T (lt) 2018-06-11
IL234663A0 (en) 2014-11-30
RU2014144284A (ru) 2016-05-27
CN104220437B (zh) 2017-11-10
WO2013150173A1 (en) 2013-10-10
PL2834233T3 (pl) 2018-09-28
TW201400478A (zh) 2014-01-01
MX2014011851A (es) 2014-11-21
CA2868611C (en) 2020-07-21
JP2015512438A (ja) 2015-04-27
ES2674945T3 (es) 2018-07-05
IL234663B (en) 2019-07-31

Similar Documents

Publication Publication Date Title
NO2021034I1 (no) pemigatinib or a pharmaceutically acceptable salt thereof
NO2022010I1 (no) ripretinib, or a pharmaceutically acceptable salt thereof
NO2021041I1 (no) remimazolam or a pharmaceutically acceptable salt thereof
FIC20230028I1 (fi) Deukravasitinibi tai sen framaseuttisesti hyväksyttävä suola
NO2023043I1 (no) Mavacamten or a pharmaceutically acceptable salt thereof
NO2021033I1 (no) Selineksor eller et farmasøytisk akseptabelt salt derav
NO2024001I1 (no) Ritlecitinib, or a pharmaceutically acceptable salt thereof
FIC20240012I1 (fi) Omaveloksoloni tai sen farmaseuttisesti hyväksyttävä suola
LUC00083I2 (en) Bictegravir or a pharmaceutically acceptable salt thereof, in particular bictegravir sodium
NO2022031I1 (no) Voxelotor or a tautomer or pharmaceutically acceptable salt thereof
NO2022044I1 (no) daridorexant eller et farmasøytisk akseptabelt salt derav, spesielt daridorexant hydroklorid
NL301161I2 (nl) zanubrutinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301234I2 (nl) maralixibat of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder maralixibatchloride
NL301006I2 (nl) Lorlatinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301155I2 (nl) abrocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NO2023040I1 (no) Atogepant or a pharmaceutically acceptable salt thereof
NL301149I2 (nl) setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NO2022002I1 (no) tasipimidine optionally in the form of a pharmaceutically acceptable salt thereof, in particular tasipimidine sulfate
NO2017057I2 (no) pibrentasvir eller et farmasøytisk akseptabelt salt derav
NO2019019I1 (no) Doravirin eller et farmasøytisk akseptabelt salt derav
CO6801645A2 (es) Nuevos inmunoconjugados
BR302012005955S1 (pt) "configuração aplicada a cadeira"
BR302012001925S1 (pt) "configuração aplicada em calota"
DK2500470T3 (da) Hoved-arbejdsvogn
NL301097I2 (nl) acalabrutinib of een farmaceutisch aanvaardbaar zout daarvan